We’ve posted new content about stem cells and cord blood that I’m excited to share it with you. Let me know what you think!
This article considers five of the most influential people operating within the iPS cell marketplace right now. These individuals are renowned industry experts, innovative thought leaders, and of course, highly-sought after speakers, advisers, and board members. Their individual opinions on iPS cell topics can substantially alter public perception…
*Ocata Therapeutics also covered this iPS cell article in an October 3rd press release. Check it out.
On September 1st, Cellular Dynamics International, a FUJIFILM company, announced news that reverberated throughout the stem cell community. The company launched the world’s largest publicly available stem cell bank, the California Institute for Regenerative Medicine (CIRM) hPSC Repository, and the availability of the first 300 iPS cell lines.
On September 7th, important follow-up news was announced. Hitachi, Ltd. and the Center for iPS Cell Research and Application at Kyoto University announced that they have reached an agreement to collaborate in building a “healthy volunteers’ iPS cell panel” that will act as a comparative database for the “disease-specific iPS cell panels” being created by CDI and CIRM.
Do you know the top 10 cities for stem cell searches on Google? It is an interesting question, isn’t it? Google searches reflect individual interest in the topic. Geographical data reflects hot spots where user interest is the greatest. Together, this data reflects important market dynamics within particular geographical areas.
The cord blood market is global in nature, and understanding dynamics limited to your region is not sufficient for making strategic, informed decisions. With nearly 500 cord blood banks operating worldwide, maturation of the global cord blood market has each company competing for market share. In 2008, a Taiwanese company became the first company to offer cord tissue storage…
In this recent 2015 analysis, BioInformant explores current rates of mesenchymal stem cell (MSC) clinical trials, analyzing the data by phase, geography, sponsors, and more. In an analysis conducted by the International Federation for Cell Biology, the majority of MSC clinical trials (41.7%) were in Phase I/II, 23.7% were in Phase II, and only 4.2% had progressed to Phase III. As such, it is clear that the bulk of MSC clinical trials remain in the early stages of development…
Access the “Global Cord Blood Industry Database 2015-16” and you can have your own searchable, sortable database of cord blood banks worldwide. Get informed now about new cord blood industry participants and identify areas of intense geographic competition.
President/CEO of BioInformant
p.s. Did you know that BioInformant is sponsoring the Perinatal Stem Cell Conference on March 2-4, 2016, as well as the “Biorepositories and Sample Management Summit” on Sept 12-14, 2015? Hit reply to this email and let me know if you’ll be at either event. I would love to meet you.